Clinical and Microbiological Characteristics of Bacteremic Pneumonia Caused by Klebsiella pneumoniae. 2022

I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

Klebsiella pneumoniae is a common pathogen of nosocomial pneumonia worldwide and community-acquired pneumonia (CAP) in Asia. Previous studies have shown that K. pneumoniae bacteremic CAP is associated with high mortality. We aimed to revisit K. pneumoniae bacteremic pneumonia in the current era and determine the risk factors associated with 28-day mortality. Between January 2014 and August 2020, adult patients with K. pneumoniae bacteremic pneumonia in a medical center in Taiwan were identified. Clinical and microbiological characteristics were compared between CAP and nosocomial pneumonia. Risk factors for 28-day mortality were analyzed using multivariate logistic regression. Among 150 patients with K. pneumoniae bacteremic pneumonia, 52 had CAP and 98 had nosocomial pneumonia. The 28-day mortality was 52% for all patients, 36.5% for CAP, and 60.2% for nosocomial pneumonia. Hypervirulent K. pneumoniae was more prevalent in CAP (61.5%) than in nosocomial pneumonia (16.3%). Carbapenem-resistant K. pneumoniae was more prevalent in nosocomial pneumonia (58.2%) than in CAP (5.8%). Nosocomial pneumonia, a higher Severe Organ Failure Assessment score, and not receiving appropriate definitive therapy were independent risk factors for 28-day mortality. In conclusion, revisiting K. pneumoniae bacteremic pneumonia in the current era showed a high mortality rate. Host factors, disease severity, and timely effective therapy affect the treatment outcomes of these patients.

UI MeSH Term Description Entries
D007710 Klebsiella Infections Infections with bacteria of the genus KLEBSIELLA. Infections, Klebsiella,Infection, Klebsiella,Klebsiella Infection
D007711 Klebsiella pneumoniae Gram-negative, non-motile, capsulated, gas-producing rods found widely in nature and associated with urinary and respiratory infections in humans. Bacillus pneumoniae,Bacterium pneumoniae crouposae,Hyalococcus pneumoniae,Klebsiella pneumoniae aerogenes,Klebsiella rhinoscleromatis
D011014 Pneumonia Infection of the lung often accompanied by inflammation. Experimental Lung Inflammation,Lobar Pneumonia,Lung Inflammation,Pneumonia, Lobar,Pneumonitis,Pulmonary Inflammation,Experimental Lung Inflammations,Inflammation, Experimental Lung,Inflammation, Lung,Inflammation, Pulmonary,Inflammations, Lung,Inflammations, Pulmonary,Lobar Pneumonias,Lung Inflammation, Experimental,Lung Inflammations,Lung Inflammations, Experimental,Pneumonias,Pneumonias, Lobar,Pneumonitides,Pulmonary Inflammations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077299 Healthcare-Associated Pneumonia Infection of the lung often accompanied by inflammation that is acquired through an interaction within a healthcare institution often through a therapeutic experience (e.g., use of catheters or ventilators). Hospital Acquired Pneumonia,Nosocomial Pneumonia,Healthcare Associated Pneumonia,Healthcare-Associated Pneumonias,Hospital Acquired Pneumonias,Nosocomial Pneumonias,Pneumonia, Healthcare-Associated,Pneumonia, Hospital Acquired,Pneumonia, Nosocomial
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D016470 Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion. Bacteremias
D017714 Community-Acquired Infections Any infection acquired in the community, that is, contrasted with those acquired in a health care facility (CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility. Community Acquired Infection,Community-Acquired Infection,Infections, Community-Acquired,Acquired Infection, Community,Acquired Infections, Community,Community Acquired Infections,Infection, Community Acquired,Infection, Community-Acquired,Infections, Community Acquired

Related Publications

I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
January 2023, Infection and drug resistance,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
March 2024, Saudi medical journal,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
March 2019, Microbial drug resistance (Larchmont, N.Y.),
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
January 1959, Pediatrie,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
October 1994, Indian pediatrics,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
February 2013, Epidemiology and infection,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
January 2013, Epidemiology and infection,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
June 2015, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
April 2023, Scientific reports,
I-Ren Chen, and Shih-Neng Lin, and Xin-Ni Wu, and Sheng-Hua Chou, and Fu-Der Wang, and Yi-Tsung Lin
July 2022, Clinical laboratory,
Copied contents to your clipboard!